Novo Nordisk sinks after its experimental obesity drug falls short of Eli Lilly’s in head-to-head trial
Novo Nordisk sank after the newest generation of its weight-loss shot, CagriSema, failed to show it was more effective than tirzepatide, the weight-loss and diabetes drug sold by Eli Lilly.
In a head-to-head trial, patients taking Novo’s drug lost 23% of their body weight after 84 weeks, compared to 25.5% with tirzepatide. Novo said it is exploring additional trials to test CagriSema, including higher-dose combinations.
The results are a hit to Novo, which was the first to bring GLP-1s to market but has now been outsold by Eli Lilly and faces increased competition from new competitors planning to bring weight-loss drugs to market. Earlier this month, Novo predicted that its sales would decline by between 5% and 13% in 2026 amid rising competition.
The company recently debuted its Wegovy pill, the first GLP-1 pill for weight loss to come to market. Early uptake has been strong, but Lilly’s pill, orforglipron, is also coming to market later this year.